Related Experiment Videos
A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice
Abdoreza Davoodi-Semiromi1, Malini Laloraya, G Pradeep Kumar
1Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida 32610, USA.
Abstract:
A number of cytokines that finely regulate immune response have been implicated in the pathogenesis or protection of type 1 diabetes and other autoimmune diseases. It is, therefore, of pivotal importance to examine a family of proteins that serve as signal transducers and activators of transcription (STATs), which regulate the transcription of a variety of cytokines. We report here a defective gene (Stat5b) located on chromosome 11 within a previously mapped T1D susceptibility interval (Idd4) in the nonobese diabetic (NOD) mice. Our sequencing analysis revealed a unique mutation C1462A that results in a leucine to methionine (L327M) in Stat5b of NOD mice. Leu(327), the first residue in the DNA binding domain of STAT proteins, is conserved in all identified mammalian STAT proteins. Homology modeling predicted that the mutant Stat5b has a weaker DNA binding, which was confirmed by DNA-protein binding assays. The inapt transcriptional regulation ability of the mutated Stat5b is proved by decreased levels of RNA of Stat5b-regulated genes (IL-2Rbeta and Pim1). Consequently, IL-2Rbeta and Pim1 proteins were shown by Western blotting to have lower levels in NOD compared with normal B6 mice. These proteins have been implicated in immune regulation, apoptosis, activation-induced cell death, and control of autoimmunity. Therefore, the Stat5b pathway is a key molecular defect in NOD mice.
Insights
A mutation in the Stat5b gene in nonobese diabetic (NOD) mice impairs immune regulation, contributing to type 1 diabetes (T1D) development. This defect affects key immune signaling pathways, offering potential therapeutic targets.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- Cytokines play a crucial role in immune responses and are implicated in type 1 diabetes (T1D) and autoimmune diseases.
- Signal transducers and activators of transcription (STATs) regulate cytokine transcription and are vital for immune system function.
Purpose of the Study:
- To investigate the role of the Signal Transducer and Activator of Transcription 5b (Stat5b) gene in the pathogenesis of type 1 diabetes in nonobese diabetic (NOD) mice.
- To identify genetic defects in Stat5b that may contribute to autoimmune disease susceptibility.
Main Methods:
- Sequencing analysis of the Stat5b gene in NOD mice to identify mutations.
- Homology modeling to predict the structural impact of the mutation.
- DNA-protein binding assays to assess DNA binding affinity.
- Quantitative real-time PCR and Western blotting to measure gene and protein expression levels of Stat5b and its downstream targets (IL-2Rbeta, Pim1).
Main Results:
- A unique C1462A mutation in the Stat5b gene of NOD mice was identified, resulting in a leucine to methionine substitution (L327M) at residue 327.
- The L327M mutation is located in the DNA binding domain and predicted to weaken Stat5b DNA binding, which was experimentally confirmed.
- Expression levels of Stat5b-regulated genes (IL-2Rbeta and Pim1) were significantly decreased in NOD mice compared to normal B6 mice at both RNA and protein levels.
Conclusions:
- The identified Stat5b mutation represents a key molecular defect in NOD mice, contributing to impaired immune regulation.
- The defective Stat5b pathway affects critical immune signaling molecules (IL-2Rbeta, Pim1), potentially leading to the development of autoimmunity and type 1 diabetes.
- Targeting the Stat5b pathway may offer a novel therapeutic strategy for type 1 diabetes and other autoimmune diseases.